Ozempic, Wegovy, and Other GLP-1 Medications: Benefits, Side Effects, and Realistic Expectations

What Are GLP-1 Medications and How Do They Work?

GLP-1 stands for glucagon-like peptide-1. It's a hormone your gut naturally releases after you eat. Its job is to signal your brain that you're full, slow down digestion, and help regulate your blood sugar. GLP-1 receptor agonists, which is the formal name for this class of drugs, mimic and amplify that signal.

The names you've probably heard are semaglutide, sold as Ozempic for diabetes and Wegovy for weight loss, and tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss. Until recently, all of them were once-weekly injections. That's changing, and I'll come back to that in a minute.

The main difference between semaglutide and tirzepatide is mechanism. Semaglutide targets one hormone pathway (GLP-1). Tirzepatide targets two (GLP-1 and GIP). That dual action tends to produce a stronger effect on appetite and fat loss for a lot of people.

What the Research Actually Shows

The most direct comparison between these two medications came from a major 2025 study in the New England Journal of Medicine. In adults with obesity but without diabetes, people on tirzepatide lost an average of 20.2% of their body weight over 72 weeks. People on semaglutide lost 13.7% over the same stretch. To put that in terms anyone can picture: if you started at 250 pounds, that's roughly 50 pounds versus 33 pounds.

Earlier studies in people with type 2 diabetes showed the same pattern. Tirzepatide lowered blood sugar more and produced greater weight loss than semaglutide after 40 weeks. Real-world data from everyday clinical practice points in the same direction.

Both medications also support heart health. Semaglutide has strong long-term evidence for reducing the risk of heart attacks and strokes in high-risk patients. Tirzepatide is showing similar cardiovascular benefits in the studies we have so far, partly because its bigger effect on weight and waist circumference carries its own heart benefits.

The New Wegovy Pill: What's Actually Different

This is probably the question I'm getting most often right now, so let's talk about it. In December 2025, the FDA approved an oral version of Wegovy, a once-daily pill that contains the same semaglutide as the injection. It officially launched in U.S. pharmacies in January 2026, so it's genuinely new, and the interest around it is enormous.

Here's what you should know.

The pill is not a watered-down version of the injection. In the OASIS 4 trial, people who took the 25 mg oral semaglutide daily and stuck with the treatment lost an average of 16.6% of their body weight at 64 weeks Applied Clinical Trials Online, which is very close to what we see with the weekly injection. About one in three participants who stayed on treatment lost 20% or more of their body weight Applied Clinical Trials Online. Those are real numbers.

The side effect profile is basically the same as the injection. Nausea, vomiting, and diarrhea are still the most common complaints Infectiousdiseaseadvisor, and there's still a boxed warning about the risk of thyroid C-cell tumors. Nothing magical about swallowing it instead of injecting it, in other words.

A few practical things matter a lot more than people expect. The pill has to be taken on an empty stomach, with a small sip of water, and then you have to wait about 30 minutes before you eat, drink anything else, or take other medications. If you're the type of person who rolls out of bed and immediately reaches for coffee, this is going to take some adjusting. I tell my patients upfront: the pill sounds easier than an injection until you realize you're doing this every single morning, on a strict schedule, for the long haul.

On the plus side, the pill doesn't need to be refrigerated, which is a real quality of life improvement for people who travel a lot. And the pricing is worth mentioning. Novo Nordisk launched the starting dose at around $149 a month for people paying cash, which is meaningfully lower than the injection has been historically. Whether your insurance covers it is a separate conversation, and one you'll want to have with your pharmacist.

Who's the pill actually for? In my view, it's a good option for patients who have a legitimate aversion to injections, patients who travel constantly, or patients whose insurance covers the oral version better. It is not a reason to avoid having a conversation about the injectable form, which still has the strongest long-term data behind it. Both are the same molecule. Both work. The best one is the one you'll actually take.

One more thing worth noting. Eli Lilly is working on their own oral GLP-1 called orforglipron, which has been submitted to the FDA for approval. The oral GLP-1 landscape is going to look different a year from now.

Side Effects: What to Expect

The most common side effects across this whole class of medications are gastrointestinal. Nausea, diarrhea, vomiting, constipation. These tend to be mild to moderate, and they're most noticeable when you're starting the medication or bumping up to a higher dose. For most of my patients, the symptoms improve over time, especially if we raise the dose slowly rather than rushing.

Serious side effects are uncommon. Somewhere around 5 to 10 percent of people stop the medication because they just can't tolerate it. But in my experience, a slower titration schedule makes a big difference for a lot of those patients.

Here's something that doesn't get talked about enough. If you stop these medications, the weight often comes back, sometimes quickly, and your blood sugar can climb again. These are not short-term fixes. They work best as part of a long-term approach that includes real changes to how you eat and how much you move.

So Which One Is Better?

Based on current evidence, tirzepatide produces greater average weight loss and better blood sugar control than semaglutide at commonly used doses. The dual-hormone mechanism seems to give it a meaningful edge for a lot of patients.

That said, semaglutide is still an excellent option, and now it comes in two forms. It may actually be the better choice if you have certain cardiovascular conditions where its long-term evidence is particularly strong, if it fits your insurance or budget more realistically, or simply if your body tolerates it well and responds the way you want. And if injections are a real dealbreaker for you, the Wegovy pill opens a door that wasn't there before.

The right medication for you isn't the one with the best average results in a clinical trial. It's the one that fits your health history, your risk profile, your lifestyle, and what you can actually sustain over time. That decision belongs in a conversation with your physician, not in a comment section on Instagram.

Realistic Expectations Before You Start

These medications can produce meaningful results. Sometimes dramatic ones. But before you start, there are a few things I want you to keep in mind.

Results vary a lot from person to person. The averages you see from clinical trials represent a range of outcomes, and your response is going to depend on your starting weight, your metabolic profile, how you eat, how active you are, and how your body tolerates the drug. Some patients lose 25 percent. Others lose 8. Both are real numbers I've seen.

These drugs work best when combined with a healthier diet and regular movement. They reduce appetite significantly, which makes it much easier to eat less, but they don't replace the habits that actually support your long-term cardiovascular and metabolic health.

Cost and access are real barriers, and I won't pretend otherwise. Not every insurance plan covers these medications, and out-of-pocket costs can be significant. The pill is changing that picture a bit, but it's still a conversation you should have openly with your doctor. Nothing to be embarrassed about.

Finally, and this one matters a lot to me. These are not cosmetic treatments. They're medical interventions approved for people with obesity, or who are overweight with at least one weight-related condition, or who have type 2 diabetes. Using them outside of appropriate medical supervision carries real risks, and I've seen those risks play out in my own practice.

The Bottom Line

Ozempic, Wegovy (injection and pill), Mounjaro, and Zepbound are a genuine advance in how we treat obesity and type 2 diabetes. They're not magic, and they're not the right choice for everyone. But for the right patient, with the right support, they can make a real difference in someone's life. I've watched it happen.

If you're wondering whether one of these medications might be appropriate for you, start with your doctor. Come in with your full health picture, your questions, and realistic expectations. The goal isn't just a lower number on the scale. It's better metabolic health, lower cardiovascular risk, and a sustainable path forward.